Better Health for All

Vivani Medical's core business is the development of miniaturized, ultra-long-acting drug implants for chronic weight management and type 2 diabetes, which are designed to improve medication adherence and patient convenience. Preclinical studies for its NPM-139 semaglutide implant showed nearly 20% placebo-adjusted weight loss in rats.

The company has no revenue from products as it is in the clinical trial phase. The first-in-human administration of the NPM-115 GLP-1 implant in the LIBERATE-1 trial was well-tolerated. The company's R&D expenses were $15.7 million for fiscal year 2024, and its total operating expenses were $23.5 million, indicating that over 66% of its operating budget is allocated to R&D for health improvement. The LIBERATE-1 trial adheres to Good Clinical Practice and has undergone ethics board review, and clinical studies in Australia comply with International Conference on Harmonization guidelines. While the company's focus on chronic weight management and type 2 diabetes has preventative aspects, no specific expenditure on preventative health measures is provided.

Fair Money & Economic Opportunity

Vivani Medical, Inc. is a biopharmaceutical company focused on developing long-term drug implants for chronic diseases.

Its core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer financial products or services. Therefore, all KPIs related to fair money and economic opportunity, such as customer share from underserved segments, pricing fairness, exploitative fees, inclusion initiatives, data accessibility, fair lending compliance, wealth-building outcomes, profit reinvestment in community finance, financial literacy programs, debt burden ratios, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to its operations.

Fair Trade & Ethical Sourcing

No quantitative data or specific information relevant to fair trade and ethical sourcing practices, such as fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles.

The company's 2022 Form 10-K, Code of Business Conduct and Ethics, and governance documents explicitly state the absence of such metrics or details.

Honest & Fair Business

Vivani Medical, Inc. has a formal whistleblower protection policy that includes a third-party compliance hotline and website for anonymous reporting.

Reports are directed to the head of the audit committee and the Compliance Officer, and the policy explicitly states that no retaliation will be tolerated. The company has not had any financial restatements in the past five years. A policy prohibiting bribery, corruption, and improper influence of government officials is in place, with specific mention of the Foreign Corrupt Practices Act (FCPA).

Kind to Animals

Vivani Medical, Inc. conducts animal testing, with preclinical weight loss data reported for its NPM-115 implant in obese rats and studies on feline obesity for OKV-119.

The company relies on animal testing for product safety and efficacy, and no alternative testing methods are mentioned as being employed by Vivani Medical. There is no explicit mention of Vivani Medical's animal testing policy in the provided articles.

No War, No Weapons

The provided articles, including Vivani Medical, Inc.'s 2022 Form 10-K and various press releases, explicitly state that no data relevant to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment, board oversight, export certifications, lobbying, humanitarian compliance, human rights due diligence, Arms Trade Treaty compliance, AI safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines, zero exposure to controversial weapons, war risk audits, annual conflict partner reviews, defense divestment, conflict mineral percentages, peace tech investment ratios, conflict zone procurement, or ethical red lines compliance rates were found.

One article discusses nonlethal weapons generally but does not link Vivani Medical, Inc. to these activities. Therefore, there is no evidence to score any of the KPIs for the 'No War, No Weapons' value.

Zero Waste & Sustainable Products

No specific, concrete evidence was found in the provided articles to assess Vivani Medical, Inc. against any of the Key Performance Indicators for 'Zero Waste & Sustainable Products'. While the company states a commitment to responsible environmental practices, including conservation, pollution prevention, and waste reduction, and mentions embedding circular economy principles, these are general statements of intent or policy.

The articles lack measurable data, specific initiatives with outcomes, or quantitative metrics related to waste diversion rates, product recyclability, packaging sustainability, take-back programs, or other relevant waste management and circularity KPIs.